24/7 Market News Snapshot 27 February, 2025 – Cassava Sciences, Inc. (NASDAQ:SAVA)
DENVER, Colo., 27 February, 2025 (247marketnews.com) – (NASDAQ:SAVA) are discussed in this article.
Cassava Sciences, Inc. (SAVA) has demonstrated significant market momentum, with its stock price opening at $2.43 and rising by 14.57% to $2.635, following a previous close of $2.30. This notable increase reflects strong investor interest, supported by a trading volume of 2.53 million shares. Market analysts are observing key resistance levels around $2.80, with indications of support near the previous lows of $2.30. The current bullish sentiment may be influenced by recent developments within the company, particularly a collaborative agreement with Yale University.
In a strategic move to enhance its research pipeline, Cassava has entered into a licensing agreement with Yale University to advance treatments for rare neurodevelopmental disorders. This partnership grants Cassava exclusive rights to a U.S. method of treatment patent related to simufilam, a proprietary small molecule drug candidate specifically designed to target filamin A. Preliminary research spearheaded by Dr. Angélique Bordey has shown that simufilam may significantly reduce seizure frequency in animal models afflicted with tuberous sclerosis complex (TSC), a disorder impacting approximately 1 in 6,000 individuals.
Rick Barry, the President and CEO of Cassava Sciences, expressed excitement regarding this partnership, emphasizing the potential of simufilam to address seizures in TSC, which commonly do not respond to existing antiepileptic medications. Cassava is committed to conducting preclinical studies in collaboration with the TSC Alliance to evaluate the therapeutic efficacy of simufilam for treating TSC-associated seizures.
Through this licensing agreement, Cassava Sciences is not only taking a decisive step forward in its clinical development efforts but also reinforcing its dedication to addressing critical medical needs within neurodevelopmental disorders.